A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
Real-World Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients Receiving Lutetium-177 Vipivotide Tetraxetan
Sponsor: Novartis Pharmaceuticals
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Number of Patients by Patient Characteristic
Time frame: Baseline
Mean PSA Level
Time frame: Baseline
Number of Patients by Number of ARPIs and Taxanes Received Before 177Lu-PSMA-617 Treatment Initiation
Time frame: Baseline
Number of Patients by Number of Doses of 177Lu-PSMA-617 Treatment From Initiation Until Discontinuation
Time frame: Up to approximately 2 years
Secondary Endpoints
Number and Percentage of Patients With a Reduction in PSA Level
Eligibility Criteria
Inclusion criteria: * Evidence of 177Lu-PSMA-617 use on or after March 23, 2022 * Date of initiation of 177Lu-PSMA-617 available in the data * Age ≥18 years at index Exclusion criteria: • None
✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →